

Accelerate biomarker discovery and target identification with Ovation IBD Omics Data

Ovation IBD Omics Data Details

- Sequenced cohort includes an initial 211 patients:
 - **WGS**
 - **RNA-Seq** on diseased and normal tissue
 - **Curated clinical data** for all patients
- Up to 2,500 IBD patients with paired normal and diseased tissue on sequencing roadmap selected from the following available patients in Ovation biobank:
 - Ulcerative Colitis: **~2,800 patients**
 - Crohn's Disease: **~1,700 patients**
 - IBD Unspecified: **~4,300 patients**
- Omics data is **linked to longitudinal clinical data** across the patient journey, including full redacted pathology reports, disease severity (from pathology), comorbidity diagnoses, therapeutic exposures, medical procedures, surgical history, and lab values (including C-reactive protein, white/red blood cell counts, albumin levels, ferritin levels, and more)

Linked Clinical Data Examples

Pathology Reports
Disease Severity
Comorbid Diagnoses
Therapeutic Exposures
Medical Procedures
Surgical History
Lab Values

Biologic Treatment Exposures in Cohort

Tofacitinib
Ustekinumab
Vedolizumab
Golimumab
Certolizumab pegol
Adalimumab
Infliximab


Ovation provides access to Diverse and Representative Populations with IBD:

~31% Hispanic patients
~1,600 Patients from underrepresented populations

Understand the longitudinal patient journey

95% of patients have >1 year of post-diagnosis data.
87% of patients have >2 years of post-diagnosis data.

~1,000 Patients with Tissue from Multiple, Sequential Timepoints in the Patient Journey




Guide the sequencing of targeted IBD cohorts of interest

In addition to our existing cohort of sequenced patients, Ovation generates novel datasets by sequencing material from our biobank of thousands of IBD tissue samples indexed with clinical annotation. Life sciences partners have the opportunity to guide the cohort selection process to align with their research objectives.



Detailed patient profiles with linked clinical data

Ovation links our omics data to a variety of clinical data sources including claims, labs, and pathology using universal token technology. Detailed, longitudinal medical history ensures researchers understand where each patient stands in their clinical journey.



Diverse patient cohorts inclusive of underrepresented populations

Ovation's IBD Omics Data includes cohorts representative of the U.S. population with geographic, ethnic, and racial diversity. This helps fill a significant gap in the current landscape of IBD genomic data, which is predominantly derived from individuals of European ancestry.



Maximize the likelihood of discovery with multiomics data

Complex diseases like IBD require integrating genomic, transcriptomic, and clinical data to identify patterns previously impossible to discern. Data delivered in analysis-ready format to client's platform of choice. Initial cohort data already ingested to DNAnexus, Paradigm4, and Amazon Redshift platforms.